The Pharma Data

MAY 7, 2021

population in just a few months, the BLA submission is an important cornerstone of achieving long-term herd immunity and containing COVID-19 in the future,” said Ugur Sahin, M.D., The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Licensing 52

Licensing Licensing Vaccination Vaccine 52

The Pharma Data

AUGUST 17, 2020

Under the agreement, Bristol Myers Squibb will become responsible for the development and any subsequent commercialization of DF6002 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding, and manufacturing. About Bristol Myers Squibb.

Licensing 52

Licensing Licensing Development Production 52

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

Drug Discovery World

MAY 5, 2023

The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. Eterna plans to use Exacis’ platform to develop engineered cell therapies containing genomic edits designed to enhance their performance.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

AUGUST 9, 2023

The company’s collaboration partner, Cancer Research UK’s Centre for Drug Development, has sponsored and will conduct the Phase I/II clinical trial. ” CD19-directed CAR T therapies Aleta’s lead development programme, ALETA-001, contains the CD19 target protein which is further linked to an CD20 antibody domain.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Licensing 52

FDA Law Blog

JUNE 3, 2021

A summary of these new state law developments is included below. Under the 2019 law, the price increase report had to contain, among other things, aggregate research and development costs, factors that led to the WAC increase, and the role of each factor’s impact on the cost.

Development 52

Development Drugs Manufacturing Pharmacy 52

World of DTC Marketing

MAY 24, 2022

DEA agents interviewed former Cerebral employees about clinician licensing issues and allegations that some patients had set up multiple accounts to obtain more drugs, Insider reported , citing sources. The problems at Cerebral as Business Insider reported that the Drug Enforcement Agency (DEA) is investigating the company.

Licensing 252

Licensing Licensing Scientist Production 252

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.

Clinical Trials 52

Clinical Trials Clinical Trials Development Trials 52

The Pharma Data

JANUARY 4, 2021

Sanofi will be responsible for all future development, manufacturing and commercialization of IPH6101/SAR443579. The companies are also currently working on the second research program. “ Innate Pharma will be eligible to up to €400m in development and commercial milestone payments as well as royalties on net sales.

Development 52

Development Antibody Drugs Containment 52

WCG Clinical

DECEMBER 13, 2023

Dietary Supplements in Research Studies When used as investigational products in a study, dietary supplements may be subject to varying regulations and requirements. Next, let’s look at considerations for study design: Study objectives are crucial in defining the specific aim of the research and the intended use of the product.

Regulation 52

Regulation Research Production Compliance 52

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. Terms of Termination. GALACTIC-HF : Results and Next Steps.

Development 52

Development Clinical Trials Clinical Trials Trials 52

The Pharma Data

NOVEMBER 30, 2020

The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”

Licensing 40

Licensing Licensing Production Development 40

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. 1 Kratz et al.,

Licensing 52

Licensing Licensing Marketing Gene Expression 52

The Pharma Data

MARCH 4, 2021

Discovered at Takeda’s Shonan, Japan research center, soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). President of Research and Development at Takeda. Under the new exclusive agreement, all global rights to soticlestat have been secured by Takeda from Ovid.

Development 52

Development Containment Medicine Clinical Trials 52

The Pharma Data

DECEMBER 12, 2020

Chief Executive Officer, Alexion , said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases.

Development 75

Development Regulation Medicine Containment 75

XTalks

MAY 1, 2023

Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. While the exact causes of ALS are not fully understood, research suggests that the mutation of SOD1 may be linked to the development of the condition.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. Earlier in his career, he ran business-development functions at Amgen and Baxter. and TAIPEI, Taiwan, Oct.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

pharmaphorum

NOVEMBER 28, 2021

The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. billion takeover of Sativex’ developer GW Pharma earlier this year.

Trials 133

Trials Drugs Licensing Licensing 133

XTalks

JANUARY 28, 2022

Kimmtrak is part of a novel class of bispecific T cell immunotherapies being developed by Immunocore. Up to 50 percent of patients will develop metastatic disease, mainly spreading to the liver, making treatment difficult and limited. Related: Cancer Blood Test Developed by University of Oxford Researchers Can Detect Metastasis.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease. Malaria Vaccine Phase II Trial.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

The Pharma Data

JANUARY 18, 2021

Experienced executive development team from Gilead Sciences. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. . SOUTH SAN FRANCISCO, Calif. ,

Development 52

Development Life Science Protein Clinical Development 52

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. After all, these failures come on top of decades and decades of research into these diseases. Why has it been so unproductive?

Medicine 59

Medicine Genome Genomics Drugs 59

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. who have been exposed to TB.

Licensing 40

Licensing Licensing FDA Approval Development 40

The Pharma Data

JANUARY 10, 2021

About MorphoSys MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases. In 2017, Tremfya (R) , developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc.,

Containment 52

Containment Clinical Development Antibody Development 52

Pfizer

FEBRUARY 16, 2023

GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. The companies intend to work with regulatory authorities, and as previously announced, 1,2 aim for Pfizer to potentially submit a Biologics License Application (BLA) to the U.S. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Pharmaceutical Technology

MAY 15, 2023

Pyridine derivatives contain one nitrogen atom in a six-membered aromatic ring and are the most extensively used heterocycles in the field of drug design, due to their promising effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents.

Antibody 130

Antibody DNA Genome Genomics 130

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent. About Cantargia.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

Drug Channels

MARCH 15, 2022

Twice a year, I research and write two comprehensive, fact-based, and nonpartisan reports on drug channel economics. The 12 chapters are self-contained and do not need to be read in order. Many sections and chapters have been expanded and/or reorganized to better cover the latest industry developments. WHAT’S GOING ON.

Pharmacy 98

Pharmacy Drugs Marketing Licensing 98

Pfizer

SEPTEMBER 27, 2022

Pfizer is focused on increasing treatment options for patients through research and development as well as innovative, technically advanced manufacturing practices. We’re proud to be strengthening our capacity to develop and produce more advanced medicines that can help improve the lives of patients. Medicines, Research.

Vaccination 45

Vaccination Vaccine Medicine Gene Therapy 45

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Client Pharma

APRIL 3, 2020

Over the past few weeks, Client-Pharma has been closely monitoring the ever-changing developments of COVID-19. Response : contain, control or minimize the impacts of any incident(s). We are continuing to work and conduct our business to remain at the service of all our clients. Please feel free to contact us in the usual way.

Licensing 52

Licensing Licensing Containment Clinical Research 52

The Pharma Data

JANUARY 19, 2021

BioInvent’s management team will also give an update on the ongoing Phase I/IIa trial of BI-1206 in combination with rituximab and BioInvent’s partner CASI Pharmaceuticals (NASDAQ: CASI) will provide an update on the development plan and potential for BI-1206 in China. LUND, Sweden , Jan. About BioInvent.

Antibody 40

Antibody Clinical Trials Clinical Trials Licensing 40

The Pharma Data

OCTOBER 15, 2020

Researchers at MSK developed naxitamab and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests related to the compounds and Y-mAbs. NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics Inc. About Y-mAbs.

Production 52

Production Development Marketing Licensing 52

The Pharma Data

JANUARY 4, 2021

The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. Sosei Heptares will now conduct a full internal review to determine a strategy for the further development and re-partnering of the program. ” About the License Agreement. . ” About the License Agreement.

Licensing 40

Licensing Licensing Development Production 40

The Pharma Data

DECEMBER 20, 2020

“With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. About BetterLife Pharma Inc. BetterLife Pharma Inc.

Drug Delivery 52

Drug Delivery Containment Production Development 52

Drug Discovery World

AUGUST 3, 2023

Even still, these approved drug products require a licensed healthcare provider’s prescription. With this in mind, the FDA claims to be committed to sound scientific research into the area and has a number of processes in place for those in the medical research community who intend to study cannabis 1.

Medicine 52

Medicine Scientist Production Regulation 52

The Pharma Data

DECEMBER 1, 2020

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Containment 52

Containment Antibody Production Engineer 52